Study on the effect of quadruple therapy with Saccharomyces burra combined with bismuth-containing agent on Helicobacter pylori positive peptic ulcer
Objective:To analyze the efficacy of saccharomyces bulla combined with bismuth-containing quadruple therapy in the treatment of Pepticulcer(PU)positive Helicobacter pylori(HP).Methods:The clinical data of 166 HP-positive PU patients admitted to our hospital from January 2022 to December 2023 were retrospectively collected.Patients were divided into control group(receiving bismuth-containing quadruple therapy,n=83)and observation group(receiving yeast burra+bismuth-containing quadruple therapy,n=83)according to different treatment regimens.The clinical efficacy,Hp eradication rate,mucosal histological score,intestinal flora,gastrointestinal function indicators,serum inflammatory factors,and adverse reactions were analyzed and compared between the two groups.The gastrointestinal function indicators and serum inflammatory factors were measured using enzyme-linked immunosorbent assay.Results:The eradication rate and total effective rate of Hp in observation group were significantly higher than those in control group(P<0.05).After treatment,the mucosal thickness,morphology,gland density and inflammatory cell infiltration score in the observation group were significantly lower than those in the control group(P<0.05).After treatment,the improvement of intestinal flora,gastrointestinal function indicators,and serum inflammatory factors in the observation group was better than that in the control group(P<0.05).There was no significant difference in the incidence of adverse reactions between the two groups(P>0.05).Conclusion:The treatment of HP positive PU patients with yeast Burra combined with bismuth-containing quadruple therapy can regulate the balance of intestinal flora,promote mucosal healing,increase the eradication rate of HP,inhibit inflammation,improve gastrointestinal function,improve curative effect,and have high safety.
万方数据
维普
